Quantum BioPharma Analyst Price Targets - Benzinga

Quantum BioPharma Ltd

QNTMNASDAQ

Trade with Public

Trade with Public

$3.24

0.299.83%

At close: Sep 3, 5:00 PM EST

$3.27

0.3211.02%

Pre-Market: 8:18 AM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Compare Stock Report

Quantum BioPharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Quantum BioPharma (QNTM).

Price Target Range — 1 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$8Upside to Avg. PT+144.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 31, 2026	Rodman & Renshaw	Michael King	Initiate	Buy	$8

Analyst Ratings News

PRO
Rodman & Renshaw Initiates Coverage On Quantum BioPharma with Buy Rating, Announces Price Target of $8

Rodman & Renshaw analyst Michael King initiates coverage on Quantum BioPharma (NASDAQ:QNTM) with a Buy rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
Quantum BioPharma Wins Buy Rating And $45 Forecast From Kingswood On Promise Of MS Drug Lucid-MS

Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech

Benzinga Newsdesk